Amgen Repatha Phase 3 Trial Meets Dual Primary Endpoints for Primary Cardiovascular Prevention

Amgen Inc. (NASDAQ:AMGN) is one of the best growth stocks to buy now. On October 2, Amgen announced that its landmark Phase 3 VESALIUS-CV clinical trial met its dual primary endpoints, confirming that Repatha (evolocumab) significantly reduced the risk of Major Adverse Cardiovascular Events/MACE in high-risk individuals without a prior history of heart attack or stroke.

This makes Repatha the first and only PCSK9 inhibitor demonstrated to reduce cardiovascular events for both primary and secondary prevention. The trial’s dual primary endpoints were both reported as statistically and clinically significant, with no new safety signals observed. The full results are scheduled for presentation at the American Heart Association Scientific Sessions on November 8.

Amgen Repatha Phase 3 Trial Meets Dual Primary Endpoints for Primary Cardiovascular Prevention

The VESALIUS-CV trial was a global, double-blind, randomized, placebo-controlled study that enrolled over 12,000 high-risk adults with known atherosclerotic cardiovascular disease/ASCVD or high-risk diabetes, but no history of heart attack or stroke.

Amgen Inc. (NASDAQ:AMGN) discovers, develops, manufactures, and delivers human therapeutics worldwide. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies.

While we acknowledge the potential of AMGN to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than AMGN and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.